Prescribing report: Reviewing SABA treatment for asthma management in adolescents and adults

Log in

For more than 50 years, people with asthma have been prescribed a short-acting beta2-agonist (SABA) as the first-line treatment for symptom relief. However, the accumulated weight of evidence has shifted and regular use of a SABA without concurrent inhaled corticosteroid (ICS) is no longer recommended for adolescents or adults.

Published: 4 August 2020

Log in if you are a prescriber, to see your personalised and practice prescribing data.

Click here if you are not a prescriber, to see the national report version.

There are currently no comments for this article.

Please login to make a comment.

Made with by the bpacnz team

Partner links